| Release date: January 2008 Expiration date: January 31, 2009 Estimated time to complete activity: 2.0 hours |
Read through all material and click "Begin activity" at the bottom of the page. |
Sponsored by
Support for this activity has been provided through an educational grant from
Activity Overview
This case-based activity provides community hepatologists and gastroenterologists expert analyses of challenging HCV cases that are encountered in daily practice. This activity allows the participants to hear multiple hepatology experts’ management approaches to specific, difficult cases involving patients with HCV. Discussion includes treatment options and treatment guidance pertaining to relevant, current, clinical cases.
Target Audience
This activity has been designed to meet the educational needs of physicians and other health care professionals involved in the care of patients with chronic hepatitis C virus (HCV) infection.
Learning Objectives
Upon completion of this activity, participants should able to:
- Identify patient- and virus-specific factors that predict response to therapy
- Formulate a management strategy for patients with advanced fibrosis
- Identify patients who may benefit from extended therapy
- Describe the strengths and limitations of current data on treatment decisions for patients with low or high viral load
Willis C. Maddrey, MD View biography
Professor of Internal Medicine
Executive Vice President for Clinical Affairs
The University of Texas
Southwestern Medical Center at Dallas
Dallas, Texas
Activity Faculty
Steven L. Flamm, MD View biography
Associate Professor
Division of Hepatology
Feinberg School of Medicine
Northwestern University
Chicago, Illinois
John B. Gross, MD View biography
Associate Professor of Medicine
Mayo Clinic College of Medicine
Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, Minnesota
Stephen A. Harrison, MD View biography
Chief of Hepatology
Associate Program Director, GI Fellowship
Brooke Army Medical Center
Fort Sam Houston, Texas
Accreditation Statement
Curatio CME Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Curatio CME Institute designates this educational activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physicians should not claim credit for this activity if credit was previously claimed for the symposium on which this Web activity is based.
Method of Participation
There are no fees for participating in this CME activity. To receive credit during the period January 2008 to January 31, 2009, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, (3) complete the posttest, and (4) complete the activity evaluation form, including the certificate information section.
Participants will then be able to print their AMA PRA Category 1 certificate for this activity.
Medium
The Internet was selected as the instructional format to accommodate the learning preferences of a significant portion of the target audience.
Disclosure
In accordance with the ACCME’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
Willis C. Maddrey, MD has disclosed the following relevant financial relationships:
| Consultant: | Alza, Pfizer, Schering-Plough, Valeant |
| Speaker: | Schering-Plough |
Steven L. Flamm, MD has disclosed the following relevant financial relationships:
| Consultant: | Schering-Plough |
| Research: | Schering-Plough |
| Speaker: | Schering-Plough |
John B. Gross, MD has disclosed the following relevant financial relationships:
| Research: | Roche, Schering-Plough, Vertex |
Steven A. Harrison, MD has disclosed the following relevant financial relationships:
| Advisor: | Roche |
| Speaker: | Roche, Schering-Plough, Valeant |
Curatio CME Institute Staff
Denise C. LaTemple, PhD, Vice President, Scientific Services, has disclosed no relevant financial relationships.
Thomas Finnegan, PhD, Medical Writer, has disclosed no relevant financial relationships.
Danielle Hesser, Program Manager, has disclosed no relevant financial relationships.
Barbara Landers, Vice President, Medical Education Programs, has disclosed no relevant financial relationships.
Brett Mutschler, CME Director, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Managing Editor, has disclosed no relevant financial relationships.
Disclaimer
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Curatio CME Institute and Schering-Plough Corporation do not recommend the use of any agent outside the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Curatio CME Institute or Schering-Plough Corporation. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
| Generic Name | Trade Name | Approved Use (if any) | Unapproved/ Investigational Use |
Interferon alfacon-1 |
Infergen® |
Treatment of chronic HCV infection in adults with compensated liver disease |
HCV infection in patients who failed to respond to pegylated interferon (PEG-IFN)–based therapy |
Peginterferon alfa-2a |
Pegasys® |
Alone or in combination with ribavirin (RBV) for treatment of adults with chronic HCV infection who have compensated liver disease and have not been previously treated with interferon-α (IFN-α) |
HCV infection in patients who relapse from previous IFN-based therapy; HCV maintenance therapy |
Peginterferon alfa-2b |
PegIntron™ |
Alone or in combination with RBV for treatment of chronic HCV infection in adults with compensated liver disease who have not been previously treated with IFN-α |
HCV infection in patients who relapse from previous IFN-based therapy; HCV maintenance therapy |
Ribavirin |
Copegus™, Rebetol®, Virazole® |
Treatment of chronic HCV infection in combination with PEG-IFN |
HCV infection in patients who relapse from previous IFN-based therapy |
Hardware/Software Requirements
- Javascript-enabled browser
- Active Internet connection
- Adobe Acrobat Reader
- Adobe Flash Player plugin v.8.0+
Privacy Policy
Curatio CME Institute collects the information provided by the user. The information is used to notify users about upcoming programs and educational information that may be of interest. The information is not shared or used for commercial purposes unless prior permission has been granted by the user.
Curatio CME Institute may collect standard Web traffic data such as time and date of visit. Curatio CME Institute uses this information to administer its Web site. Browsing activity is recorded to form aggregate and anonymous demographic information, which is used as described above. Curatio CME Institute does not sell or offer to sell any user data, including registration and billing information, to any third parties for commercial purposes. Curatio CME Institute does, when required, provide the minimum subset of information to third parties that are responsible for accreditation of and issuance of certification for CME/CE tests. By participating in the Web-based activity, the user agrees that Curatio CME Institute has full permission to provide this minimum subset of information to the third parties as required by law.
For CME questions, please contact cmeinfo@curatiocme.com or call (610) 363-1619 ext. 113. If you experience technical difficulties, please contact helpdesk@axis-healthcare.com.